Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV: A Real-World Data from the Spanish BICSTaR Cohort.

HIV/AIDS (Auckland, N.Z.)·2025

Same author

Current prevalence of hepatitis delta diagnosis in Valencia, Spain.

Scientific reports·2025

Same author

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

Same author

Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.

AIDS and behavior·2024

Same author

Current characteristics of patients with hepatitis C virus: results from an automated alert system.

Revista espanola de enfermedades digestivas·2024

Same author

Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention.

Frontiers in public health·2024

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

[Resistance to darunavir].

Miguel García Deltoro¹

¹Unidad de Enfermedades Infecciosas. Consorcio Hospital General Universitario. Valencia. España. med001007@saludalia.com.

Enfermedades Infecciosas Y Microbiologia Clinica

|February 7, 2009

Summary

Darunavir (DRV) resistance is predicted by baseline viral phenotype and specific mutations. Accumulation of mutations, particularly V32I and I54L, correlates with diminished virological response in HIV patients.

Area of Science:

Virology
Pharmacology
HIV Therapeutics

Background:

Darunavir (DRV) is a key protease inhibitor for HIV treatment.
Understanding DRV resistance is crucial for optimizing therapy and managing treatment failure.

Purpose of the Study:

To explore the resistance profile of darunavir (DRV).
To identify predictors of virological response to DRV.
To analyze mutation patterns associated with DRV failure.

Main Methods:

Pooled analysis of week 24 data from POWER 1, 2, and 3 studies.
Inclusion of data from DUET 1 and 2 placebo arms.
Assessment of darunavir fold change (EC50) and DRV mutation scores (2006 and 2007).

Main Results:

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Experiment Videos

Last Updated: Jun 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Baseline darunavir fold change (EC50) and DRV mutation scores are strong predictors of virological response.
Three or more mutations in the DRV score list were associated with diminished response.
V32I and I54L were commonly selected mutations upon DRV failure in multiresistant patients.
DRV demonstrated a lower frequency of virological failure and mutations compared to lopinavir.

Conclusions:

Genotypic and phenotypic resistance assays provide valuable insights into DRV efficacy.
The DRV score, particularly the 2007 revision, aids in predicting treatment outcomes.
Darunavir exhibits a favorable resistance profile, even in treatment-experienced patients.